NANOPARTIDES AS PROBES FOR DNA BINDING

   
 

LEAD INVENTOR:
Susannah Gal

TEAM MEMBERS:
Chuan-Jian Zhong

CONTACT INFORMATION:

Dr. Eugene Krentsel
Director of Technology Transfer and Innovation Partnerships
Tel: 607-777-5871
Fax: 607-777-5788 krentsel@binghamton.edu

 

DESCRIPTION:

DNA binding proteins are used in all cell systems to regulate gene expression. If this exquisitely controlled system is disrupted say by mutation of the DNA binding protein, disease likely is the result. One common disease associated with the loss of DNA binding protein activity is cancer. Present DNA binding assays require extraction of proteins from tissues and then incubation with DNA (often radiolabeled or labeled with another detectable modification) followed by separation of bound and free DNA. These assays are time consuming and many are not quantitative. They also cannot be conducted in a living cell or tissue.

The DNA binding assay described in this disclosure would increase the sensitivity of detection of a DNA binding protein and also improve the speed with which the assay could be completed. In addition, the components to detect DNA binding in the assay are not toxic for a cell and thus would allow the detection and potential titration of DNA binding proteins in living tissues and cells. This invention should allow for fast and easier detection of disease causing gene mutations that require much more extensive procedures at this point for their identification.

ADVANTAGES:

Present DNA binding assays require sometime long procedures andlor radioactivity to detect the action of these important proteins. This assay is likely to allow the quantitative measurement of DNA binding in a rapid manner and without radioactivity. It is also a dynamic assay while most other assays are not. The fact that these gold nanoparticles are non-toxic to cells should potentially allow this assay to work in living cells and tissues for an in vivo measurement of DNA binding proteins. At present, to our knowledge there is no rapid in vivo assay for DNA binding proteins.

DISADVANTAGES:

At present, we have tested only parts of this invention while other parts will be tested in the coming weeks. Thus we have not tested all of the components of the system together at the time of this disclosure. Present assays for DNA binding proteins have been tested In a number of systems.

PATENT STATUS:

Patent application is being finalized